Research Publications

Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice.

J Antimicrob Chemother. Sep 2018

Phage-derived lysins as potential agents for eradicating biofilms and persisters.

Drug Discovery Today. 23(4), April 2018

Restoration of sensitivity of a diverse set of drug-resistant Staphylococcus clinical strains by bactericidal protein P128.

J Med Microbiol. 2018 Mar;67(3):296-307

Efficacy of Novel Antistaphylococcal Ectolysin P128 in a Rat Model of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Antimicrob Agents Chemother. Jan 2018

Efficient Killing of Planktonic and Biofilm Embedded Coagulase-Negative Staphylococci by Bactericidal Protein P128.

Antimicrob Agents Chemother. 30 May 2017

Bacteriophage lysins as antibacterials.

Critical Care (2017) 21:99

Antibiofilm activity and synergistic inhibition of S. aureus biofilms by bactericidal protein P128 in combination with antibiotics.

Antimicrob Agents Chemother. 26 Sep 2016

Fighting sinus-derived Staphylococcus aureus biofilms in vitro with a bacteriophage-derived muralytic enzyme.

International Forum of Allergy & Rhinology.17 December, 2015

Bacteriophage-derived CHAP domain protein, P128, kills Staphylococcus cells by cleaving interpeptide cross-bridge of peptidoglycan.

Microbiology. 01 Oct, 2014

Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128.

Bacteriophage. 02 October, 2013

Efficacy of anti-staphylococcal protein P128 for the treatment of canine pyoderma- potential applications.

Veterinary Research Communications. 22 March, 2013

Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128.

BMC Research Notes. 8 June, 2012

Antistaphylococcal activity of bacteriophage derived chimeric protein P128.

BMC Microbiology. 22 March, 2012

A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein.

BMC Microbiology. 11 October, 2011

Simulated hatchery system to assess bacteriophage efficacy against Vibrio harveyi.

Diseases of Aquatic Organisms. 2 December, 2014

Book Chapter: Phage therapy-Bacteriophage and phage derived products as anti-infective drugs; Drug Discovery Targeting Drug-Resistant Bacteria. (2020).

United Kingdom: Elsevier Science. Pg 301-356

Therapeutic potential of staphylococcal bacteriophages for nasal decolonization of Staphylococcus aureus in mice.

Advances in Microbiology. 8 March, 2013

Determining the Minimum Inhibitory Concentration of Bacteriophages: Potential Advantages.

Advances in Microbiology. June 2013

Staphylococcus bacteriophage tails with bactericidal properties: New findings.

Biotechnology and Applied Biochemistry. 4 December, 2012

Use of prophage free host for achieving homogenous population of bacteriophages: new findings.

Virus Research. 13 August, 2012

Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection.

BMC Microbiology. 31 August, 2011

Book Chapter: Phage therapy-Bacteriophage and phage derived products as anti-infective drugs; Drug Discovery Targeting Drug-Resistant Bacteria. (2020).

United Kingdom: Elsevier Science. Pg 301-356

Research Publications

P128 related publications:

Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice.

Phage-derived lysins as potential agents for eradicating biofilms and persisters.

Restoration of sensitivity of a diverse set of drug-resistant Staphylococcus clinical strains by bactericidal protein P128.

Efficacy of Novel Antistaphylococcal Ectolysin P128 in a Rat Model of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Efficient Killing of Planktonic and Biofilm Embedded Coagulase-Negative Staphylococci by Bactericidal Protein P128.

Bacteriophage lysins as antibacterials.

Antibiofilm activity and synergistic inhibition of S. aureus biofilms by bactericidal protein P128 in combination with antibiotics.

Fighting sinus-derived Staphylococcus aureus biofilms in vitro with a bacteriophage-derived muralytic enzyme.

Bacteriophage-derived CHAP domain protein, P128, kills Staphylococcus cells by cleaving interpeptide cross-bridge of peptidoglycan.

Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128.

Efficacy of anti-staphylococcal protein P128 for the treatment of canine pyoderma- potential applications.

Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128.

Antistaphylococcal activity of bacteriophage derived chimeric protein P128.

A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein.

Simulated hatchery system to assess bacteriophage efficacy against Vibrio harveyi.

Other Publications:

Book Chapter: Phage therapy-Bacteriophage and phage derived products as anti-infective drugs; Drug Discovery Targeting Drug-Resistant Bacteria. (2020).

Therapeutic potential of staphylococcal bacteriophages for nasal decolonization of Staphylococcus aureus in mice.

Determining the Minimum Inhibitory Concentration of Bacteriophages: Potential Advantages.

Staphylococcus bacteriophage tails with bactericidal properties: New findings.

Use of prophage free host for achieving homogenous population of bacteriophages: new findings.

Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection.

Book Chapter: Phage therapy-Bacteriophage and phage derived products as anti-infective drugs; Drug Discovery Targeting Drug-Resistant Bacteria. (2020).